Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04811027
Title Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Immutep S.A.S.
Indications

hypopharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma

oropharynx cancer

laryngeal squamous cell carcinoma

Therapies

Eftilagimod alpha + Pembrolizumab

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ESP | BEL


No variant requirements are available.